Literature DB >> 29344257

Involvement of soluble B7-H3 in combination with the serum inflammatory cytokines interleukin-17, -8 and -6 in the diagnosis of hepatocellular carcinoma.

Fenghuang Xu1, Junzhu Yi1, Feifei Wang2, Weiwei Wang1, Zhuoya Wang1, Jiangnan Xue1, Xiying Luan1.   

Abstract

Previous studies have demonstrated that B7-H3, and the inflammatory cytokines interleukin (IL)-17, IL-8 and IL-6, are involved in the development of a variety of tumors. The objectives of the present study were: i) To investigate the association between soluble B7-H3 (sB7-H3) and cytokine levels of IL-17, IL-8 and IL-6 in the serum of patients with hepatocellular carcinoma (HCC); and ii) to determine their potential value for use in HCC diagnosis. Serum sB7-H3, IL-17, IL-8 and IL-6 levels in the HCC patients and healthy control subjects were measured using ELISA. The accuracy of each of these biomarkers in HCC diagnosis was compared using a receiver operating characteristic curve and the area under the curve (AUC). A logistic regression model was used to investigate the accuracy of diagnosing HCC when evaluated using combined determinations of sB7-H3, IL-17, IL-8 and IL-6 levels. The data demonstrated that serum levels of sB7-H3, IL-17, IL-8 and IL-6 were significantly increased in HCC patients compared with those in the healthy control group. Serum sB7-H3 levels were positively associated with serum IL-17, whereas serum IL-8 levels were negatively correlated with serum IL-17 levels. The AUC values for sB7-H3, IL-17, IL-8 and IL-6 were 83.2, 65.7, 95.3 and 97.0%, respectively, and indicated that all four biomarkers exhibited a statistically significant capacity for diagnosing HCC. Using the logistic regression model, the AUC value, sensitivity and specificity, as determined for the combination of the four biomarkers, were 99.2, 96.67 and 97.14%, respectively. This was significantly greater than that achieved when any single biomarker was used alone in the logistic regression model to assess their accuracy in HCC diagnosis. The optimum cutoff value of the predicted probability obtained by the combination of sB7-H3, IL-17, IL-8 and IL-6 in the regression model was 0.5745. To conclude, the present study revealed that there exists a positive association between serum sB7-H3 and IL-17 levels in HCC patients. Determinations involving the combination of serum sB7-H3, IL-17, IL-8 and IL-6 levels demonstrate great potential for use in HCC diagnosis.

Entities:  

Keywords:  B7-H3; hepatocellular carcinoma; interleukin-17; interleukin-6; interleukin-8

Year:  2017        PMID: 29344257      PMCID: PMC5755218          DOI: 10.3892/ol.2017.7215

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  Leukocyte-associated immunoglobulin-like receptor-1 expressed in epithelial ovarian cancer cells and involved in cell proliferation and invasion.

Authors:  Qizhi Cao; Aili Fu; Shude Yang; Xiaoli He; Yue Wang; Xiaoshu Zhang; Jiadi Zhou; Xiying Luan; Wenzheng Yu; Jiangnan Xue
Journal:  Biochem Biophys Res Commun       Date:  2015-02-03       Impact factor: 3.575

2.  IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.

Authors:  D V Jovanovic; J A Di Battista; J Martel-Pelletier; F C Jolicoeur; Y He; M Zhang; F Mineau; J P Pelletier
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

Review 3.  Probiotic species in the modulation of the anticancer immune response.

Authors:  Luciana Marinelli; Gian Carlo Tenore; Ettore Novellino
Journal:  Semin Cancer Biol       Date:  2017-08-24       Impact factor: 15.707

4.  B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression.

Authors:  Feifei Wang; Guoyan Wang; Tongshen Liu; Guohua Yu; Guangbo Zhang; Xiying Luan
Journal:  Cancer Invest       Date:  2014-04-30       Impact factor: 2.176

Review 5.  Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy.

Authors:  Xianda Zhao; Subbaya Subramanian
Journal:  Pharmacol Ther       Date:  2017-07-15       Impact factor: 12.310

6.  Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains.

Authors:  Peter Steinberger; Otto Majdic; Sophia V Derdak; Katharina Pfistershammer; Stefanie Kirchberger; Christoph Klauser; Gerhard Zlabinger; Winfried F Pickl; Johannes Stöckl; Walter Knapp
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

7.  Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.

Authors:  Seo Young Park; Jiyou Han; Jong Bin Kim; Man-Gil Yang; Yoon Jun Kim; Hee-Joung Lim; Su Yeon An; Jong-Hoon Kim
Journal:  Eur J Cancer       Date:  2013-10-22       Impact factor: 9.162

8.  Differential expression of 2IgB7-H3 and 4IgB7-H3 in cancer cell lines and glioma tissues.

Authors:  Zhenxin Wang; Jianfeng Yang; Yanbo Zhu; Yun Zhu; Bin Zhang; Yinghui Zhou
Journal:  Oncol Lett       Date:  2015-08-14       Impact factor: 2.967

9.  IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study.

Authors:  Jung-Ta Kao; Chun-Lung Feng; Cheng-Ju Yu; Shu-Mei Tsai; Ping-Ning Hsu; Yao-Li Chen; Yi-Ying Wu
Journal:  BMC Gastroenterol       Date:  2015-04-25       Impact factor: 3.067

10.  Liver Cancer Detection by a Simple, Inexpensive and Effective Immunosensor with Zinc Oxide Nanoparticles.

Authors:  Congo Tak-Shing Ching; Nguyen van Hieu; Teng-Yun Cheng; Lin-Shien Fu; Tai-Ping Sun; Ming-Yen Liu; Su-Hua Huang; Yan-Dong Yao
Journal:  Sensors (Basel)       Date:  2015-11-20       Impact factor: 3.576

View more
  3 in total

Review 1.  Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.

Authors:  Chuan Liu; Guangwei Zhang; Kanghui Xiang; Yohan Kim; Roxane R Lavoie; Fabrice Lucien; Ti Wen
Journal:  Cancer Immunol Immunother       Date:  2021-11-05       Impact factor: 6.968

Review 2.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

3.  Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through miR-122 downregulation with increased risk of primary liver cancer initiation.

Authors:  Imène Gasmi; Camilia Machou; Aurélie Rodrigues; Arthur Brouillet; Trung Cong Nguyen; Benoit Rousseau; Adrien Guillot; Christophe Rodriguez; Vanessa Demontant; Yeni Ait-Ahmed; Julien Calderaro; Alain Luciani; Jean-Michel Pawlotsky; Fouad Lafdil
Journal:  Int J Biol Sci       Date:  2022-02-21       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.